Combination therapy with immune agonists and senescence-inducing agents delivers promise for immunotherapeutic success in pancreatic cancer
J Leukoc Biol
.
2024 Oct 29:qiae234.
doi: 10.1093/jleuko/qiae234.
Online ahead of print.
Authors
Renee R Anderko
1
2
,
Amer H Zureikat
1
2
3
,
Tullia C Bruno
2
4
5
6
Affiliations
1
Department of Surgery, Division of Surgical Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
2
UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
3
Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
4
Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
5
Cancer Immunology and Immunotherapy Program (CIIP), UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
6
Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
PMID:
39471419
DOI:
10.1093/jleuko/qiae234
No abstract available
Keywords:
PDAC; TME remodeling; immunotherapy; nanoparticles; tertiary lymphoid structures.